News for Healthier Living

Oxeia Pioneering First Potential FDA-Approved Concussion Treatment

Oxeia Biopharmaceuticals today launched an equity crowdfunding campaign on StartEngine to advance OXE103, a therapy for persistent concussion symptoms that demonstrated an 85% responder rate in Phase 2a clinical testing.

January 7, 2026


January 17 2026

January 16 2026

January 15 2026

January 14 2026

January 13 2026

January 12 2026

January 11 2026

January 10 2026

January 9 2026

January 8 2026

January 7 2026

January 6 2026

January 5 2026

January 4 2026